Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

Lilly claims compounds for women's health

Oct. 18, 1996

Atosiban efficacy in treating preterm labor

Oct. 11, 1996

Yamanouchi awaits marketing approval for new contraceptive

Oct. 11, 1996

Improved formulation of Testoderm available in U.S.

Oct. 11, 1996

Muse approvable for treatment of impotence

Oct. 11, 1996

Aldose reductase inhibitor in phase III at Fujisawa

Oct. 11, 1996

Antidiabetic agents from Yamanouchi's clinical pipeline

Oct. 11, 1996

New approval for Lilly's Humalog

Oct. 11, 1996

UCSF scientists discover protein involved in insulin resistance

Oct. 11, 1996

Novel, highly potent antihyperglycemic agents from SmithKline Beecham

Oct. 11, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 6, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 6, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.